Lu177 treatments
Published by Isotopia, 23th May 2022 177Lu PSMA I&T – Prostate-Specific Membrane Antigen (PSMA) Therapy is becoming a popular treatment choicefor men experiencing advanced prostate cancer with metastatic or treatment-resistant prostate tumors. Lu177 PSMA I&T is an extensively investigated PSMA radioligand for Radionuclide Therapy (RLT) utilizing the Theranostic concept that delivers beta-particle radiation to PSMA-expressing cells […]
Nuclear imaging in Parkinson’s disease- The past, the present, and the future.
Published by Isotopia, 16th May 2022 Published by Isotopia, 16th May 2022 We are proud to share this exciting article written by Haim Golan, Olga Volkov, and Eli Shalom. The review analyzed the history of Parkinson’s disease-related imaging development and its current condition and pointed out some understudied aspects to be investigated. The present review […]
Overcoming Lutetium-177 Production and Supply Challenges
Published by Isotopia, 21th April 2022 Published by Isotopia, 21th April 2022 Lutathera and Lu-PSMA 617 are FDA-approved therapeutic radiotracers used to treat neuroendocrine tumors and prostate cancer. As the demand for radioisotopes increases, producers are challenged to supply the market with sufficient products to accommodate the heightened demand without compromising product quality and patient […]
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Take home message: Take home message: The vision study is an international phase 3 trial Comparing between best medical cares versus best medical care + radioligand therapy with 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. It was shown that radioligand therapy with 177Lu-PSMA-617 improves overall survival and radiographic progression-free survival when used as an […]
Vision study – Research on Prostate Cancer
177Lu-PSMA-617 radioligand therapy in mCRPC – VISION phase 3 trial The results from the “ProPSMA” Study, that was recently published in JAMA Oncology by Prof. Michael Hofman et al, showed that PSMA-targeted imaging with 68Ga-PSMA-11 is more accurate and valuable in guiding the management of prostatic cancer patients in comparison with the current practice of […]
proPSMA study
The “proPSMA” study results proved the superiority of 68Ga-PSMA imaging over conventional imaging with CT and Bone Scan in Prostate Cancer Results from a randomised controlled trial – the ProPSMA Study – involving 300 prostate cancer (PC) patients find that 68Ga-PSMA PET-CT is more accurate than current practice of conventional imaging with CT and Bone […]
18F-DOPA use in Parkinsonism
On October 10, 2019, the FDA approved the use of 18F-DOPA in positron emission tomography to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). This approval came more than a decade after 18F-DOPA usage has been approved in Europe. Fluorodopa (18F-DOPA) is a radioactive diagnostic […]
Lutetium 177 production (Lu177 production)
Carrier Added (CA) and Non-Carrier Added (NCA) The production of 177-Lu 177-Lu is a fully synthetic isotope. there are 2 ways to produce 177-Lu: The direct route – by irradiation of 176-Lu enriched target with thermal neutrons in a nuclear reactor. Following irradiation, the target material is simply dissolved in diluted acid, dispensed and steam sterilized.The […]
PERSONALIZED NUCLEAR MOLECULAR CANCER THERAPY
For decades, physicians and patients knew three classic treatments for cancer: Surgery Chemotherapy Radiation therapy New times have come, and new therapies are available like: Immunotherapy Hormone therapy Gene therapy Targeted therapy But the most novel and advanced cancer treatment is the nuclear-molecular targeted therapy with radioactive agents. At ISOTOPIA we are enabling personalized medicine […]
Prostate cancer
Innovative metastatic prostate cancer treatment with 177-Lu-PSMA. Prostate cancer is the most common cancer in older men (over 50) and the second cause of cancer death in men. In most patients, it is a localized disease that will be treated by surgery or radiation. Approximately 15% of patients will be diagnosed with metastatic disease already at the […]
